14.17

3.20% 0.44

Neogenomics Inc (NEO)

Overview News Price History Option Chain Financials Why NEO Down? Discussions Forecast Stock Split

Neogenomics Inc stock is traded at $14.17, with a volume of 7.13M. It is up +3.20% in the last 24 hours and up +52.86% over the past month. NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Previous Close:

$13.73

Open:

$13.69

24h Volume:

7.13M

Relative Volume:

2.94

Market Cap:

$1.85B

Revenue:

$745.97M

Net Income/Loss:

$-99.21M

P/E Ratio:

-18.33

EPS:

-0.7729

Net Cash Flow:

$-5.09M

1W Performance:

+27.31%

1M Performance:

+52.86%

6M Performance:

+15.39%

1Y Performance:

+97.91%

1-Day Range:

$13.60

$14.23

1-Week Range:

$10.96

$14.23

52-Week Range:

$4.72

$14.23

Neogenomics Inc Stock (NEO) Company Profile

Name

Neogenomics Inc

Sector

Healthcare (1096)

Industry

Diagnostics & Research (48)

Phone

(239) 768-0600

Address

9490 NEOGENOMICS WAY, FORT MYERS, FL

Employee

2,500

Twitter

@NeoGenomics

Next Earnings Date

2026-08-04

Latest SEC Filings

NEO's Discussions on Twitter

Compare NEO vs TMO, DHR, IDXX, A, NTRA

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NEO Neogenomics Inc	14.17	1.79B	745.97M	-99.21M	-5.09M	-0.7729
TMO Thermo Fisher Scientific Inc	513.03	187.95B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	196.19	136.75B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	551.50	43.78B	4.45B	1.10B	1.06B	13.59
A Agilent Technologies Inc	136.01	38.27B	7.23B	1.41B	1.09B	4.979
NTRA Natera Inc	261.91	37.34B	2.50B	-226.32M	71.51M	-1.6412

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-25	Downgrade	BTIG Research	Buy → Neutral
Jul-29-25	Downgrade	William Blair	Outperform → Mkt Perform
May-15-25	Initiated	Guggenheim	Neutral
Apr-30-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jan-13-25	Downgrade	The Benchmark Company	Buy → Hold
Dec-10-24	Initiated	Jefferies	Buy
May-01-24	Resumed	Craig Hallum	Buy
Dec-29-23	Reiterated	BTIG Research	Buy
Aug-21-23	Upgrade	Stephens	Equal-Weight → Overweight
May-16-23	Downgrade	Raymond James	Outperform → Mkt Perform
May-09-23	Upgrade	BTIG Research	Neutral → Buy
Feb-24-23	Upgrade	The Benchmark Company	Hold → Buy
Feb-01-23	Upgrade	Needham	Hold → Buy
Aug-26-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-22-22	Downgrade	Needham	Buy → Hold
Jun-03-22	Initiated	Piper Sandler	Overweight
Mar-29-22	Downgrade	BofA Securities	Buy → Neutral
Mar-29-22	Downgrade	Stephens	Overweight → Equal-Weight
Jan-18-22	Resumed	Stephens	Overweight
Dec-16-21	Initiated	Cowen	Outperform
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-03-21	Initiated	Goldman	Buy
Feb-25-21	Resumed	Needham	Buy
Feb-25-21	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-28-21	Initiated	Truist	Buy
Dec-11-20	Resumed	BTIG Research	Buy
Oct-28-20	Reiterated	Needham	Buy
Sep-09-20	Initiated	Morgan Stanley	Overweight
Aug-28-20	Initiated	Guggenheim	Buy
Jul-29-20	Reiterated	Needham	Buy
Jun-25-20	Initiated	BofA/Merrill	Buy
Apr-21-20	Resumed	Stephens	Overweight
Mar-02-20	Resumed	Craig Hallum	Buy
Feb-28-20	Upgrade	First Analysis Sec	Outperform → Strong Buy
Jan-23-20	Downgrade	First Analysis Sec	Strong Buy → Outperform
Oct-30-19	Reiterated	Needham	Buy
May-01-19	Reiterated	Needham	Buy
Mar-29-19	Reiterated	Needham	Buy
Jan-03-19	Initiated	Needham	Buy
Oct-24-18	Upgrade	First Analysis Sec	Outperform → Strong Buy
Aug-21-18	Initiated	Leerink Partners	Outperform
May-02-18	Downgrade	First Analysis Sec	Overweight → Equal-Weight
Sep-11-17	Downgrade	BTIG Research	Buy → Neutral
Aug-24-17	Initiated	Gabelli & Co	Buy
Dec-15-16	Initiated	Cantor Fitzgerald	Overweight

View All

Neogenomics Inc Stock (NEO) Latest News

08:08 AM

Enterprise value to revenue forward of NeoGenomics, Inc. – NASDAQ:NEO - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of NeoGenomics, Inc. – LSX:120159 - TradingView

Jun 26, 2026

A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack - Yahoo Finance

Jun 26, 2026

Jun 25, 2026

NEO Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Neogenomics stock hits 52-week high at 13.74 USD - Investing.com UK

Jun 25, 2026

Neogenomics stock hits 52-week high at 13.74 USD By Investing.com - Investing.com South Africa

Jun 25, 2026

NeoGenomics (NASDAQ: NEO) director receives new RSU and stock option grants - Stock Titan

Jun 25, 2026

NeoGenomics (NEO) director Carolyn Starrett files initial Form 3 - Stock Titan

Jun 25, 2026

NeoGenomics, Inc. Announces Appointment of Carolyn Starrett to Board of Directors - marketscreener.com

Jun 25, 2026

NeoGenomics Taps AI Veteran for Board, Signaling Data-Driven Future - BriefGlance

Jun 25, 2026

NeoGenomics Appoints Carolyn Starrett to Board of Directors - citybiz

Jun 25, 2026

NeoGenomics appoints Carolyn Starrett to board of directors - Investing.com

Jun 25, 2026

NeoGenomics appoints Carolyn Starrett to board of directors By Investing.com - Investing.com Canada

Jun 25, 2026

NeoGenomics appoints Carolyn S. Starrett to its Board - TradingView

Jun 25, 2026

Carolyn Starrett joins NeoGenomics (NEO) board, expanding oncology and AI expertise - Stock Titan

Jun 25, 2026